Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-05-22 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于恩威医药股份有限公司2023年度持续督导培训情况的报告
Audit Report / Information Classification · 90% confidence The document is a report from CITIC Securities regarding the 2023 annual continuous supervision training conducted for Enwei Pharmaceutical Co., Ltd. It details the training session's basic information, participants, content, and conclusions. The document is a formal report on a regulatory or compliance training activity rather than a financial report, earnings release, or management discussion. It does not contain financial statements or results, nor is it an announcement of voting results or capital changes. It is a standalone report related to regulatory compliance and supervision training, which fits best under Audit Report / Information (AR) as it relates to regulatory oversight and internal control training rather than a full annual report or other categories. FY 2023
2024-05-22 Chinese
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2023 by Enwei Pharmaceutical Co., Ltd. It details the company's dividend distribution plan, including cash dividends and capital reserve stock transfers, the shareholder meeting approval, record dates, ex-dividend dates, and shareholding adjustments. The document is an announcement of the implementation of the equity distribution (dividend and stock transfer) plan approved at the annual shareholders meeting. It does not contain full financial statements or comprehensive financial performance data, nor is it a full annual report or interim report. It is also not a proxy statement or voting result announcement. The document is relatively short (4387 characters) and primarily serves to inform shareholders about the dividend distribution details and related dates. Therefore, it fits best under the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2024-05-16 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2023年度跟踪报告
Management Reports Classification · 95% confidence The document is titled as a "2023年度跟踪报告" (2023 Annual Tracking Report) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding 恩威医药股份有限公司 (Enwei Pharmaceutical Co., Ltd.). The content includes detailed oversight and review activities by the sponsor (保荐人), covering information disclosure, internal controls, fundraising supervision, governance, and regulatory compliance issues throughout the year 2023. It also discusses regulatory measures and corrective actions taken by the sponsor and the company. The document is comprehensive, contains substantive analysis and findings related to the company's operations and compliance for the year 2023, and is not merely an announcement or a brief summary. It is not a full Annual Report (10-K) of the company itself, nor is it an audit report or a regulatory filing. Instead, it is a detailed sponsor's tracking report on the company for the year, which fits the category of a Management Report or Management Discussion and Analysis (MDA), as it provides management's detailed explanation of company performance, governance, and regulatory compliance over the period. The document length (9379 characters) supports it being a substantive report rather than a brief announcement. Therefore, the most appropriate classification is Management Reports (MDA).
2024-05-15 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2023 Annual General Meeting (AGM) resolution announcement for Enwei Pharmaceutical Co., Ltd. It details the convening, attendance, and voting results of the 2023 Annual General Meeting held in May 2024. The content includes the approval of various proposals such as the 2023 board work report, supervisory board report, financial statements, annual report, profit distribution plan, auditor appointment, and remuneration plans. The document is primarily focused on the official announcement of the voting results and resolutions passed at the AGM, rather than the full annual report or financial statements themselves. The length is 4579 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-13 Chinese
北京金杜（成都）律师事务所关于恩威医药股份有限公司2023年年度股东大会之法律意见书
Regulatory Filings
2024-05-13 Chinese
关于回购公司股份的进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Enwei Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or comprehensive financial data but focuses on the update of the company's share buyback activity. The length is short (1329 characters), and the content is a progress announcement rather than a full report. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-05-06 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.